Dernières nouvelles pour Psyence Biomedical (NASDAQ:PBM) Stock

Psyence Biomedical

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical Ltd

PACIFIC BAY MINERALS LTD by Pacific Bay Minerals Ltd.

Pacific Bay Minerals Ltd

PACIFIC BOOKER MINERALS by Pacific Booker Minerals Inc.

Pacific Booker Minerals Inc

PGIM S&P 500 Buffer 20 ETF - March

PT BUMI RESOURCES TBK by PT Bumi Resources TBK

PT Bumi Resources Tbk

PT BUMI RESTBK UNSP/ADR by PT Bumi Resources TBK

PGIM S&P 500 Buffer 20 ETF - May

WIIM

PBM stock has given up its prior gain. Psyence Biomedical shares were trading higher after the company announced it, along with PsyLabs, achieved a breakthrough in GMP-aligned high-purity ibogaine production.

Shares of Psyence Biomedical Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) are surging Thursday morning following an announcement from the company and its strategic partner, PsyLabs. 
What To Know: The companies <a href="https://www.benzinga.com/pressreleases/25/07/g46752439/psyence-biomeds-strategic-collaboration-with-psylabs-yields-breakthrough-in-high-purity-ibogaine-p">reported</a> the successful production of a high-purity, GMP-aligned Ibogaine Total Alkaloid extract, a significant milestone in the field of psychedelic medicine.
According to the release, the naturally derived extract was verified by an accredited third-party laboratory to have met all microbial safety standards for food-grade consumption. 
The company says this achievement validates Psyence BioMed's strategic investment in PsyLabs. Psyence BioMed first acquired an equity stake in the producer in 2024 and expanded its investment in 2025.
Psyence BioMed, the <a href="https://www.benzinga.com/pressreleases/25/07/g46752439/psyence-biomeds-strategic-collaboration-with-psylabs-yields-breakthrough-in-high-purity-ibogaine-p">breakthrough</a> is a crucial step toward creating a reliable supply of scalable, compliant and ethically sourced psychedelic Active Pharmaceutical Ingredients. 
PsyLabs officials confirmed their commitment to refining processes to achieve even higher purity levels and are currently expanding production capacity to meet growing global demand.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PBM shares are trading higher by 2.6% to $5.52 Thursday morning. The stock has a 52-week high of $364.63 and a 52-week low of $2.92.
Read Also: <a href="https://www.benzinga.com/news/health-care/25/07/46755354/soligenix-drug-matches-fda-approved-amgen-therapy-in-rare-inflammatory-disease">Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial</a>
<h2 class="wp-block-heading">How To Buy PBM Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Psyence Biomedical&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

News

Psyence BioMed (PBM) Shares Soar On Ibogaine Production Breakthrough

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 1% on Thursday.
Following the market opening Thursday, the Dow traded up 0.24% to 44,566.33 while the NASDAQ rose 1.26% to 21,395.66. The S&amp;P 500 also rose, gaining, 0.76% to 6,411.57.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46756402/top-2-risk-off-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Risk Off Stocks That May Keep You Up At Night This Month</a>
Leading and Lagging Sectors Communication services shares jumped by 2.9% on Thursday.
In trading on Thursday, health care stocks dipped by 0.7%.
Top Headline
Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) reported better-than-expected fourth-quarter financial results and issued strong forecast for the current quarter on Wednesday.
Microsoft reported fourth-quarter revenue of $76.44 billion, up 17% year-over-year. The revenue total beat a Street consensus estimate of $73.80 billion according to data from Benzinga Pro. The company reported fourth-quarter earnings per share of $3.65, beating a Street consensus estimate of $3.37.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares shot up 73% to $2.1793 after the company reported better-than-expected second-quarter EPS and sales.</li>
<li>Shares of VerifyMe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) got a boost, surging 64% to $1.1250 after the company announced it entered into a 3-year UPS Digital Channel Program Agreement with the United Parcel Service.</li>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares were also up, gaining 55% to $8.32 after the company announced it, along with PsyLabs, achieved a breakthrough in GMP-aligned high-purity ibogaine production.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Pulmonx Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) shares dropped 37% to $1.9750 after the company reported second-quarter financial results and cut its FY25 sales guidance below estimates. Also, Piper Sandler downgraded the stock from Overweight to Neutral and cut its price target from $9 to $2.5, while D. Boral Capital cut its price target from $17 to $16.</li>
<li>Shares of Align Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) were down 31% to $140.66 after the company missed second-quarter earnings estimates and issued soft third-quarter guidance.</li>
<li>GRI Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) was down, falling 31% to $1.43 as the company reported 6-week interim biomarker results from Phase 2a idiopathic pulmonary fibrosis study.</li>
</ul>
Commodities In commodity news, oil traded down 0.8% to $69.46 while gold traded up 0.1% at $3,354.30.
Silver traded down 2.8% to $36.675 on Thursday, while copper fell 21.4% to $4.3860.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.4%, while Spain's IBEX 35 Index gained 0.2%. London's FTSE 100 rose 0.2%, Germany's DAX 40 declined 0.5% and France's CAC 40 fell 0.5% during the session.
Asia Pacific Markets
Asian markets closed mostly lower on Thursday, with Japan's Nikkei 225 gaining 1.02%, Hong Kong's Hang Seng falling 1.60%, China's Shanghai Composite dipping 1.18% and India's BSE Sensex falling 0.36%.
Economics
<ul class="wp-block-list">
<li>The core PCE price index rose 0.3% from the previous month in June.</li>
<li>Personal spending rose 0.3% month-over-month in June, while personal income rose by 0.3% month-over-month to $25.794 trillion.</li>
<li>U.S. initial jobless claims rose by 1,000 from the previous week to 218,000 in the fourth week of July, compared to market estimates of 224,000.</li>
<li>U.S. employment costs rose by 0.9% in the second quarter.</li>
<li>U.S.-based employers announced job cuts of 62,075 in July.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46755797/amazon-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call-2">Amazon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ALGN

ALPS ETF Trusthen & Steers Global Realty Majors ETF

LUNG

MSFT

SNGX

VRME

Nasdaq Surges Over 1%; Microsoft Posts Upbeat Earnings

Psyence Biomedical shares are trading higher after the company announced it, along with PsyLabs, achieved a breakthrough in GMP-aligned high-purity ibogaine production.

<h3>Gainers</h3>
<ul>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock rose 62.6% to $8.78 during Thursday's pre-market session. The company's market cap stands at $3.8 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares rose 42.3% to $2.96. The company's market cap stands at $4.9 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock rose 25.23% to $4.02. The company's market cap stands at $1.6 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares rose 21.59% to $1.52. The market value of their outstanding shares is at $4.0 million. </li>
<li>Alignment Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) shares rose 19.21% to $15.5. The company's market cap stands at $2.4 billion. The company's, Q2 earnings came out yesterday. </li>
<li>TransMedics Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) stock moved upwards by 16.75% to $125.75. The market value of their outstanding shares is at $3.6 billion. The company's, Q2 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Align Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) shares decreased by 31.6% to $139.21 during Thursday's pre-market session. The company's market cap stands at $14.7 billion. As per the press release, Q2 earnings came out yesterday. </li>
<li>Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) shares declined by 19.69% to $2.53. The company's market cap stands at $125.3 million. As per the press release, Q2 earnings came out yesterday. </li>
<li>Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) shares decreased by 17.89% to $6.2. The market value of their outstanding shares is at $157.7 million. </li>
<li>Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) stock fell 12.76% to $3.42. The market value of their outstanding shares is at $527.2 million. </li>
<li>Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) stock decreased by 11.5% to $1.0. The company's market cap stands at $34.0 million. </li>
<li>Pheton Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTHL#NASDAQ">PTHL</a>) shares fell 10.91% to $0.98. The company's market cap stands at $15.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALHC

DYAI

ENSC

NVCT

ONCO

PRME

PTHL

TMDX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Psyence BioMed And PsyLabs Achieve Breakthrough In GMP-Aligned High-Purity Ibogaine Production For Global Psychedelic API Supply

<h3>Gainers</h3>
<ul>
<li>Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) stock increased by 186.2% to $39.41 during Monday's regular session. The company's market cap stands at $521.4 million. </li>
<li>Scilex Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>) shares rose 28.9% to $15.42. The market value of their outstanding shares is at $67.5 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) shares moved upwards by 25.55% to $0.4. The market value of their outstanding shares is at $19.1 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock moved upwards by 20.99% to $0.62. The company's market cap stands at $8.1 million. </li>
<li>Hyperion DeFi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPD#NASDAQ">HYPD</a>) stock rose 17.59% to $9.05. The market value of their outstanding shares is at $39.3 million. </li>
<li>X4 Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) stock moved upwards by 17.3% to $2.13. The company's market cap stands at $13.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock decreased by 66.2% to $0.12 during Monday's regular session. The company's market cap stands at $91.9 million. </li>
<li>Can Fite Biofarma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CANF#AMEX">CANF</a>) shares declined by 27.61% to $0.71. The company's market cap stands at $12.6 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) stock decreased by 24.76% to $0.55. The company's market cap stands at $25.2 million. </li>
<li>TAO Synergies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOX#NASDAQ">TAOX</a>) stock decreased by 17.37% to $6.95. The company's market cap stands at $19.5 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 16.52% to $9.6. The company's market cap stands at $8.2 million. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) shares decreased by 14.66% to $5.59. The company's market cap stands at $96.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADAP

ADIL

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CANF

CELC

CLDI

HYPD

SCLX

TAOX

XFOR

12 Health Care Stocks Moving In Monday's Intraday Session

Shares of Celcuity Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) rose sharply in pre-market trading after the company announced it will disclose the topline results of the PIK3CA Wild-Type Cohort from the Phase 3 <a href="https://www.benzinga.com/quote/CELC">VIKTORIA-1 trial</a>.
Celcuity jumped 12.6% to $15.50 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>CEA Industries Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VAPE#NASDAQ">VAPE</a>) shares gained 804.5% to $80.28 in pre-market trading after gaining 4% on Friday.</li>
<li>Mill City Ventures III Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCVT#NASDAQ">MCVT</a>) rose 79.8% to $10.60 in pre-market trading after jumping 219% on Friday.</li>
<li>Majestic Ideal Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MJID#NASDAQ">MJID</a>) shares jumped 44.2% to $2.61 in pre-market trading after falling 5% on Friday.</li>
<li>Anghami Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGH#NASDAQ">ANGH</a>) climbed 38.3% to $0.64 in pre-market trading. On July 23, the company appointed James Cooke, a senior executive from Warner Bros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>), to its Board of Directors—bringing industry expertise and potentially strengthening strategic ties. Additionally, to boost compliance and potentially enhance investor appeal, Anghami shareholders also approved a 1-for-10 reverse stock split.</li>
<li>22nd Century Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) gained 34.6% to $4.13 in pre-market trading after gaining 4% on Friday. 22nd Century Group recently announced several tobacco brands are partnering with the organization to expand their availability and awareness.</li>
<li>Nvni Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) surged 25.7% to $0.53 in pre-market trading.</li>
<li>Aeye Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIDR#NASDAQ">LIDR</a>) surged 19.5% to $5.30 in pre-market trading. AEye shares jumped 52% on Friday after the company announced it filed an amendment to update its maximum number of the company&#8217;s common shares up to an aggregate of $23.728 million placement shares.</li>
<li>INmune Bio Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NYSE">INMB</a>) gained 19.5% to $3.24 in pre-market trading.</li>
<li>Hotel101 Global Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBNB#NASDAQ">HBNB</a>) rose 15.2% to $2.84 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Sidus Space Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) dipped 47.5% to $1.06 in pre-market trading after the company announced the pricing of public offering.</li>
<li>180 Life Sciences Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) declined 15% to $2.55 in pre-market trading after gaining over 40% on Friday.</li>
<li>Eightco Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCTO#NASDAQ">OCTO</a>) dipped 12.9% to $2.15 in pre-market trading after jumping 72% on Friday.</li>
<li>Psyence Biomedical Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares tumbled 11.7% to $10.16 in pre-market trading after gaining 15% on Friday.</li>
<li>Zooz Power Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZOOZ#NASDAQ">ZOOZ</a>) declined 10.7% to $3.27 in pre-market trading after gaining 29% on Friday. Maxim Group analyst Tate Sullivan, on July 24, downgraded Zooz Power from Buy to Hold.</li>
<li>ATAI Life Sciences NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) fell 9.3% to $3.23 in pre-market trading after the company announced the Phase 2b trial of Inidascamine in patients with cognitive impairment associated with schizophrenia did not meet its primary endpoint.</li>
<li>Fusion Fuel Green PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) fell 9.2% to $6.29 in pre-market trading. Fusion Fuel Green shares jumped 47% on Friday after the company announced its subsidiary has confirmed several new projects.</li>
<li>Next Technology Holding Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) fell 6.2% to $2.10 in pre-market trading after declining more than 5% on Friday.</li>
<li>KB Financial Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KB#NYSE">KB</a>) shares fell 5.1% to $81.50 in pre-market trading after declining 5% on Friday.</li>
<li>Cantor Equity Partners I Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEPO#NASDAQ">CEPO</a>) fell 4.3% to $11.35 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46653283/sp-500-notches-5th-consecutive-record-close-following-strong-earnings-investor-sentiment-edges-lower-but-fear-index-remains-in-greed-zone">S&amp;P 500 Notches 5th Consecutive Record Close Following Strong Earnings: Investor Sentiment Edges Lower, But Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

ANGH

ATAI

ATNF

CEPO

HBNB

HTOO

INMB

LIDR

MCVT

MJID

NVNI

Next Technology Holding Inc. - Ordinary Shares

NXTT

OCTO

SIDU

VAPE

XXII

ZOOZ

Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>NextCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTC#NASDAQ">NXTC</a>) stock rose 55.0% to $7.95 during Thursday's after-market session. The company's market cap stands at $12.1 million. </li>
<li>Pheton Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTHL#NASDAQ">PTHL</a>) shares increased by 10.55% to $31.42. The company's market cap stands at $341.7 million. </li>
<li>X4 Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) shares moved upwards by 10.38% to $2.02. The company's market cap stands at $10.7 million. </li>
<li>Titan Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTNP#NASDAQ">TTNP</a>) shares increased by 8.69% to $5.58. The company's market cap stands at $4.2 million. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) stock increased by 8.67% to $1.44. The company's market cap stands at $23.5 million. </li>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock rose 7.47% to $3.84. The market value of their outstanding shares is at $6.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock declined by 16.2% to $0.05 during Thursday's after-market session. The market value of their outstanding shares is at $10.2 million. </li>
<li>NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) stock declined by 14.58% to $0.77. The market value of their outstanding shares is at $44.7 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock decreased by 12.58% to $0.12. The market value of their outstanding shares is at $1.5 million. </li>
<li>Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) shares decreased by 11.12% to $3.12. The market value of their outstanding shares is at $449.0 million. </li>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) shares declined by 8.34% to $11.0. The company's market cap stands at $43.2 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock decreased by 8.31% to $9.16. The company's market cap stands at $5.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABSI

COEP

HCTI

IRIX

NMTC

NXTC

SNOA

TNFA

TTNP

12 Health Care Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock increased by 54.8% to $1.41 during Tuesday's regular session. The company's market cap stands at $4.8 million. </li>
<li>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares rose 51.65% to $468.44. The company's market cap stands at $8.8 billion. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares increased by 37.06% to $4.32. The market value of their outstanding shares is at $75.4 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) shares moved upwards by 25.75% to $5.86. The market value of their outstanding shares is at $421.9 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares moved upwards by 23.04% to $6.54. The market value of their outstanding shares is at $3.7 million. </li>
<li>IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) stock rose 18.58% to $188.5. The company's market cap stands at $27.5 billion. As per the press release, Q2 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) stock declined by 75.5% to $3.02 during Tuesday's regular session. The market value of their outstanding shares is at $950.0 million. </li>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) shares declined by 28.44% to $2.19. The market value of their outstanding shares is at $113.2 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock decreased by 26.93% to $2.05. The company's market cap stands at $16.9 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock declined by 20.9% to $1.45. The company's market cap stands at $7.3 million. </li>
<li>Anbio Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNNN#NASDAQ">NNNN</a>) shares declined by 17.67% to $42.4. The market value of their outstanding shares is at $2.2 billion. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares decreased by 16.54% to $0.11. The company's market cap stands at $1.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

BDMD

CELU

FTRE

MEDP

NNNN

PLRZ

REPL

12 Health Care Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares increased by 8.8% to $0.3 during Tuesday's after-market session. The market value of their outstanding shares is at $18.8 million. </li>
<li>Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) stock rose 8.14% to $0.69. The market value of their outstanding shares is at $111.0 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) shares increased by 8.0% to $0.88. The company's market cap stands at $14.5 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) stock moved upwards by 7.77% to $0.97. The company's market cap stands at $14.7 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares moved upwards by 6.66% to $1.12. The market value of their outstanding shares is at $2.3 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock rose 6.36% to $0.33. The market value of their outstanding shares is at $1.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares decreased by 26.2% to $2.14 during Tuesday's after-market session. The market value of their outstanding shares is at $77.5 million. </li>
<li>Cardiff Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) stock decreased by 16.76% to $3.08. The company's market cap stands at $204.8 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) stock decreased by 16.26% to $0.24. The company's market cap stands at $20.7 million. As per the press release, Q4 earnings came out today. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock decreased by 14.35% to $5.97. The market value of their outstanding shares is at $17.2 million. </li>
<li>Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) shares declined by 8.28% to $0.75. The market value of their outstanding shares is at $17.6 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares declined by 6.89% to $4.8. The company's market cap stands at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACXP

BMEA

CGTX

CRDF

EYEN

GOVX

HSDT

IBIO

IRWD

SLRX

XAIR

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) stock increased by 67.5% to $6.35 during Friday's pre-market session. The market value of their outstanding shares is at $23.6 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) stock rose 20.19% to $1.25. The market value of their outstanding shares is at $23.4 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock increased by 10.92% to $5.79. The market value of their outstanding shares is at $3.3 million. </li>
<li>VSee Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) stock increased by 10.28% to $1.3. The market value of their outstanding shares is at $20.4 million. </li>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) stock moved upwards by 9.98% to $0.98. The market value of their outstanding shares is at $45.8 million. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) stock moved upwards by 9.52% to $1.38. The company's market cap stands at $111.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) stock declined by 23.0% to $3.5 during Friday's pre-market session. The market value of their outstanding shares is at $40.0 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares fell 20.28% to $0.41. The market value of their outstanding shares is at $3.1 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares fell 15.95% to $0.28. The market value of their outstanding shares is at $7.7 million. </li>
<li>NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) shares fell 14.8% to $11.17. The company's market cap stands at $366.3 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares declined by 13.23% to $0.36. The company's market cap stands at $1.7 million. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares decreased by 13.0% to $0.58. The company's market cap stands at $25.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLRX

BMGL

CERO

CLGN

ENTO

GNPX

HBIO

IMAB

NPCE

RVPH

VSEE

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) stock moved upwards by 178.2% to $3.95 during Friday's regular session. The company's market cap stands at $253.7 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) stock increased by 26.52% to $0.72. The company's market cap stands at $24.2 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) shares increased by 25.62% to $22.11. The market value of their outstanding shares is at $3.7 billion. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock moved upwards by 25.47% to $0.28. The company's market cap stands at $40.0 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) stock moved upwards by 25.33% to $1.88. The company's market cap stands at $94.0 million. The company's, Q1 earnings came out yesterday. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares increased by 22.8% to $5.43. The market value of their outstanding shares is at $3.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares declined by 67.3% to $0.01 during Friday's regular session. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares fell 22.48% to $0.01. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares decreased by 19.63% to $0.65. The company's, Q2 earnings came out yesterday. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares fell 18.92% to $0.04. </li>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock declined by 18.44% to $3.15. The company's market cap stands at $33.9 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Aytu BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYTU#NASDAQ">AYTU</a>) stock declined by 18.15% to $2.12. The company's market cap stands at $13.0 million. As per the press release, Q3 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACAD

APDN

ATPC

AYTU

BDSX

INZY

LTRN

NCNA

RANI

12 Health Care Stocks Moving In Friday's Intraday Session

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

<h3>Gainers</h3>
<ul>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares rose 68.2% to $4.81 during Thursday's pre-market session. The market value of their outstanding shares is at $3.9 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock moved upwards by 36.2% to $0.02. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock rose 28.98% to $0.89. The market value of their outstanding shares is at $5.8 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) stock moved upwards by 11.56% to $3.28. The market value of their outstanding shares is at $123.5 million. </li>
<li>Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) shares moved upwards by 10.63% to $1.55. The company's market cap stands at $48.5 million. </li>
<li>Conmed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNMD#NYSE">CNMD</a>) stock increased by 10.42% to $54.23. The market value of their outstanding shares is at $1.6 billion. As per the press release, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) stock fell 31.3% to $6.61 during Thursday's pre-market session. The market value of their outstanding shares is at $454.5 million. As per the press release, Q1 earnings came out today. </li>
<li>Organon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGN#NYSE">OGN</a>) stock decreased by 16.71% to $10.77. The market value of their outstanding shares is at $2.7 billion. As per the news, the Q1 earnings report came out today. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) stock decreased by 14.65% to $2.68. The market value of their outstanding shares is at $12.2 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares declined by 12.08% to $0.4. The market value of their outstanding shares is at $1.8 million. </li>
<li>Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) stock decreased by 11.72% to $6.78. The market value of their outstanding shares is at $2.0 billion. The company's, Q1 earnings came out today. </li>
<li>Greenwich LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLSI#NASDAQ">GLSI</a>) stock fell 10.9% to $9.0. The company's market cap stands at $119.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRV

ARVN

BCDA

CNMD

FOLD

GLSI

LGMK

NAOV

SERA

<h3>Gainers</h3>
<ul>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) stock increased by 61.0% to $12.98 during Friday's regular session. The company's market cap stands at $8.7 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares increased by 42.96% to $2.26. The company's market cap stands at $31.0 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares rose 23.66% to $0.28. The market value of their outstanding shares is at $3.9 million. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) stock rose 15.48% to $7.68. The market value of their outstanding shares is at $45.5 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock rose 15.06% to $3.97. The company's market cap stands at $2.1 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock rose 14.45% to $0.53. The market value of their outstanding shares is at $2.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) shares declined by 36.9% to $7.86 during Friday's regular session. The company's market cap stands at $25.4 million. </li>
<li>Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock fell 36.76% to $23.21. The company's market cap stands at $17.1 billion. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares fell 33.66% to $0.6. The company's market cap stands at $9.0 million. </li>
<li>VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) stock declined by 23.75% to $1.43. The company's market cap stands at $21.1 million. </li>
<li>Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) stock decreased by 21.4% to $1.02. The company's market cap stands at $85.6 million. </li>
<li>Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) stock declined by 21.1% to $15.47. The market value of their outstanding shares is at $101.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CYCC

INTS

JAGX

NDRA

RBOT

SMMT

STRO

SXTC

VYNE

<a href="https://www.biospace.com/press-releases/psyence-biomed-announces-usd-500-000-follow-on-investment-in-psylabs-and-global-ibogaine-supply-agreement">https://www.biospace.com/press-releases/psyence-biomed-announces-usd-500-000-follow-on-investment-in-psylabs-and-global-ibogaine-supply-agreement</a>
New York, New York--(Newsfile Corp. - April 15, 2025) - Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) ("Psyence BioMed" or the "Company") today announced a strategic follow-on investment of USD $500,000 into PsyLabs, a privately-held company specializing in the production of psychedelic active pharmaceutical ingredients (APIs) and extracts for research, clinical trials, and drug development. This follow-on investment underscores Psyence BioMed's commitment to building a vertically integrated, multi-asset psychedelics biotech platform with robust supply chain security and clinical development capabilities.
This new capital investment builds on the exclusive, royalty-bearing IP licensing agreement formalized between the two companies in September 2024, following an initial investment where Psyence BioMed acquired an 11.13% equity stake in PsyLabs. Under the terms of that agreement, PsyLabs supplies Psyence BioMed with pharmaceutical-grade, EU-GMP, nature-derived (non-synthetic) psilocybin for use in future clinical trials and eventual commercialization in substance use disorders (SUD).
In parallel with this financial commitment, Psyence BioMed has secured an exclusive right of first refusal in respect of the worldwide supply of pharmaceutical-grade, nature-derived Ibogaine. Under this agreement, PsyLabs will grant Psyence BioMed a right of first refusal to acquire the exclusive rights to a dedicated supply of Ibogaine for evaluation in the treatment of SUD, including Alcohol Use Disorder (AUD). This exclusive partnership further strengthens Psyence BioMed's integrated development strategy, ensuring access to high-quality psychedelic compounds to support its growing clinical pipeline and diversification into multiple therapeutic areas.
Ibogaine, a naturally occurring psychoactive substance derived from the Tabernanthe iboga plant, has shown promise in early-stage research for its unique ability to interrupt SUDs, offering a novel approach to addiction treatment. Existing treatment options for SUDs and AUD remain limited in effectiveness, highlighting the urgent need for new solutions.

Contracts

'Psyence BioMed Announces $500,000 Follow-On Investment In PsyLabs And Global Ibogaine Supply Agreement' - BioSpace

<h3>Gainers</h3>
<ul>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares increased by 190.8% to $8.55 during Tuesday's pre-market session. The company's market cap stands at $6.4 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock moved upwards by 32.42% to $0.58. The market value of their outstanding shares is at $2.6 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock rose 32.33% to $2.38. The company's market cap stands at $3.5 million. </li>
<li>NAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) shares moved upwards by 27.36% to $2.67. The company's market cap stands at $13.1 million. </li>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) stock increased by 22.32% to $3.89. The company's market cap stands at $8.6 million. </li>
<li>Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) shares increased by 20.07% to $27.51. The market value of their outstanding shares is at $1.2 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock decreased by 51.2% to $3.66 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.0 million. </li>
<li>Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) stock decreased by 46.37% to $1.4. The market value of their outstanding shares is at $109.6 million. </li>
<li>CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) stock declined by 30.25% to $8.05. The company's market cap stands at $209.5 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares fell 19.02% to $0.7. The company's market cap stands at $8.0 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares declined by 16.44% to $0.27. The company's market cap stands at $2.0 million. </li>
<li>Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) stock decreased by 16.17% to $1.09. The market value of their outstanding shares is at $52.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BJDX

CVRX

MYNZ

NAYA

PCRX

PHLT

PTIX

STTK

SXTP

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock rose 198.8% to $0.78 during Monday's after-market session. The company's market cap stands at $12.1 million. As per the press release, Q4 earnings came out today. </li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares rose 51.02% to $70.3. The company's market cap stands at $382.2 million. As per the press release, Q4 earnings came out today. </li>
<li>Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) stock rose 18.42% to $2.25. The company's market cap stands at $309.5 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock moved upwards by 17.7% to $1.13. The market value of their outstanding shares is at $6.6 million. The company's, Q4 earnings came out 2 days ago. </li>
<li>Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) stock moved upwards by 16.29% to $3.24. The market value of their outstanding shares is at $8.8 million. As per the press release, Q4 earnings came out today. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) shares moved upwards by 10.48% to $0.55. The market value of their outstanding shares is at $9.3 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock fell 11.2% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $2.3 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares declined by 8.9% to $2.51. The company's market cap stands at $3.7 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares decreased by 8.61% to $0.85. The market value of their outstanding shares is at $60.8 million. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) stock declined by 7.83% to $0.34. The market value of their outstanding shares is at $17.8 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares decreased by 6.67% to $0.56. The market value of their outstanding shares is at $2.5 million. </li>
<li>Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) stock declined by 6.64% to $4.08. The market value of their outstanding shares is at $84.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADVM

BIAF

BNGO

CMPX

CTOR

EVOK

NUTX

PSTV

TLPH

12 Health Care Stocks Moving In Monday's After-Market Session

Press Releases

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Financing

Psyence Biomed Announces $2.0 Million Private Placement

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Health Care

Management

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

Loop Industries (Nasdaq: LOOP) Unveils Game-Changing Twist™ Polyester Made Entirely from Textile Waste – More Stocks Inside

CSE:PSYG

Comments

Psyence Biomedical

Actualités

Dernières nouvelles pour Psyence Biomedical (NASDAQ:PBM) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL